- Completion of office deal by GenesisCare paves the way for a £42 million state-of-the-art cancer care and treatment centre at Thorpe Park, Leeds
- Due to open in 2026, the pioneering centre will offer innovative cancer care to patients in the North of England, who previously had to travel to GenesisCare in Oxford for such specialist treatments
LEEDS, 9 September 2025: A multidisciplinary team at Cushman & Wakefield has acted for GenesisCare -the UK’s leading independent cancer care provider which specialises in complex cancers - in securing 1200 Century Way at Thorpe Park in Leeds on a leasehold basis.
Planning approval has just been granted to convert the premises from a 27,000 sq ft office into a new state-of-the-art oncology and haematology treatment facility, due to open in 2026. It will be the 15th and largest in GenesisCare’s UK network of treatment centres and will house two of the world’s most advanced radiotherapy treatment systems.
At the new facility, radiotherapy treatments can be personalised in real-time, using both MRI and CT imaging, offering patients treatment precisely tailored to their specific cancer. This will establish GenesisCare in Leeds as one of a small group of cancer centres worldwide with the ability to provide adaptive radiotherapy and systemic therapy for every patient who would benefit from this innovative approach.
Cushman & Wakefield’s Healthcare Markets team provides a full property advisory service to GenesisCare, including acquisitions and disposals across the UK and Europe.
James Hanson, Healthcare Transactions at Cushman & Wakefield, said: “It was imperative that we aligned GenesisCare’s location strategy with their business strategy and future vision. Using data and analytics, and in conjunction with our colleagues based in Leeds, we identified Thorpe Park as the most appropriate site for GenesisCare’s expansion plans. To align with their ESG goals and for speed and efficiency, they were looking for an existing building to repurpose and transform into a state-of-the-art healthcare facility. Accessibility was also a major consideration, from the perspectives of both patients and clinicians based at the healthcare centre. We are extremely proud to have advised GenesisCare on this deal and look forward to further supporting their ambitious growth plans in providing accessible world-class cancer care that will positively impact patient outcomes.”
Jake Lipschitz in Cushman & Wakefield’s national Healthcare team, said: “GenesisCare has impressive plans to invest £42 million into the creation of a one-of-a-kind cancer treatment centre. We identified the building at Thorpe Park as the right location to develop the facility for several reasons, primarily its location and accessibility via road and public transport, but also, importantly, access to adequate power supply. It was incredibly rewarding to represent GenesisCare on such an important acquisition, and one that will benefit patients and families across the North of England for many years to come.”
Justin Hely, CEO UK & Europe GenesisCare, said: “Receiving this planning approval is a significant milestone and step forward in GenesisCare’s commitment to providing advanced cancer treatment for patients in the North of England and promoting breakthrough research. By incorporating the latest medical technologies and fostering a collaborative environment for leading healthcare professionals, we aim to enhance patient outcomes and establish new benchmarks in oncology care. The new centre is not merely a structure; it epitomises hope, innovation, and our unwavering dedication to fighting cancer with utmost compassion and excellence. We are delighted with the outcome and quality of service provided to us by Cushman & Wakefield.”
